| Name | Title | Contact Details |
|---|
BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.
Targeted Genetics Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Progenics is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Arcxis Biotechnologies Inc is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Synosia Therapeutics is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.